Journal article
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies
- Abstract:
- Human serum IgG contains multiple glycoforms which exhibit a range of binding properties to effector molecules such as cellular Fc receptors. Emerging knowledge of how the Fc glycans contribute to the antibody structure and effector functions has opened new avenues for the exploitation of defined antibody glycoforms in the treatment of diseases. Here, we review the structure and activity of antibody glycoforms and highlight developments in antibody glycoengineering by both the manipulation of the cellular glycosylation machinery and by chemoenzymatic synthesis. We discuss wide ranging applications of antibody glycoengineering in the treatment of cancer, autoimmunity and inflammation.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.3MB, Terms of use)
-
- Publisher copy:
- 10.1016/j.bbagen.2016.04.016
Authors
- Publisher:
- Elsevier
- Journal:
- BBA: General Subjects More from this journal
- Volume:
- 1860
- Issue:
- 8
- Pages:
- 1655–1668
- Publication date:
- 2016-01-01
- Acceptance date:
- 2016-04-16
- DOI:
- EISSN:
-
1872-8006
- ISSN:
-
0304-4165
- Pubs id:
-
pubs:616204
- UUID:
-
uuid:0b2e8dd8-bff6-40c7-9e1b-14150b28494c
- Local pid:
-
pubs:616204
- Source identifiers:
-
616204
- Deposit date:
-
2016-04-18
- ARK identifier:
Terms of use
- Copyright holder:
- Ngoc Phuong Lan Le et al
- Copyright date:
- 2016
- Notes:
-
Copyright © 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record